Metrics as of 10/16/2026, 12:25 AM (Berlin time), refresh in progress.
CorMedix Stock
CorMedix Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Joseph Todisco
- Employees
- 191
- Market cap
- $581 M
- IPO
- 13/05/2010
CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a…
CorMedix stock: price history
1D
+0.9%
1W
+1.9%
1M
-3.9%
6M
+4.6%
YTD
-35.9%
1Y
-29.7%
2Y
-26.1%
5Y
+50.7%
10Y
-35.1%
Next earnings date
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~61% stronger price swings than usual
Ask the agents about CorMedix
Analyst assessment of CorMedix
PRICE TARGET LOW
US$14.00
CONSENSUS
US$14.50
MEDIAN
US$14.50
PRICE TARGET HIGH
US$15.00
0
STRONG BUY
8
BUY
0
HOLD
0
SELL
0
STRONG SELL
8
TOTAL · Buy
As of: 14/08/2026
CorMedix stock metrics
P/E
3.1
P/B
1.27
EV/EBITDA
1.88
RETURN ON EQUITY
5.6%
NET MARGIN
25.5%
DEBT/EQUITY
0.31
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
84.5%
FLOAT SHARES
65,887,896
AVG. DAILY VOLUME (30D)
957,979
Insider transactions (SEC)
Dillione Janet
Zelnick Kaufman Beth
Hurlburt Elizabeth
Blum Susan
Attention
1 mention today in US forums, about the same as yesterdayPrice since yesterday: +0.9%
Forums (Reddit)
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about CorMedix stock
What does CorMedix do?
CorMedix Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Joseph Todisco, the company employs around 191 people.
The IPO was on 13/05/2010; the stock trades on NASDAQ under the ticker CRMD.
What do analysts say about CorMedix stock?
8 analysts rate the stock, the consensus is Buy (as of 14/08/2026).
The average price target is US$14.50, ranging from US$14.00 to US$15.00, with a median of US$14.50.
This is an external assessment, not a statement by Market Jury.
When does CorMedix report next?
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly 61% stronger than usual.
Does CorMedix pay a dividend?
No, CorMedix currently does not pay a dividend.
Which stocks are comparable to CorMedix?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get CorMedix stock analyzed?
Clicking "Analyze stock" lets five strategies assess CorMedix against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.